This paper describes a microfluidic-based telemedicine system for insulin detection and conveying the results digitally to physicians located off-site through the Internet. The communication infrastructure is designed to transfer the digital information from the assay site to established healthcare facilities where trained medical professionals can directly assist the detection process and provide diagnosis. The insulin detection device of the telemedicine system is an integrated polydimethysiloxane (PDMS) microfluidic device consisting of two pneumatic micropumps and one micromixer. The insulin detection protocol is based on microbeads-based double-antibody sandwich immunoassay coupled with luminal-hydrogen peroxide (H 2 O 2 ) chemiluminescence. A photometer detects the peak value of the luminous intensity, which indicates the insulin concentration of the patient plasma sample tested. The calibration curves of the insulin detection protocol have been quantified. The insulin detection limit of the microfluidic system is 4310 210 mol/l, which meets the common requirement of the current clinical studies of diabetes. Multiple immune indicators of diabetes can potentially be detected synchronously by the microfluidic system, thus providing physicians with integrative results necessary for accurate diagnosis via the Internet. The combination of microfluidic devices and telemedicine strategy offers new opportunities for diabetes care and screening, especially in rural areas where patients must travel long distances to physicians for healthcare information that might be obtained more cost effectively by local, less-trained personnel.
Introduction
Diabetes mellitus (DM) is one of the most prevalent chronic diseases caused by deficiency or diminished effectiveness of endogenous insulin (Leu and Zonszein, 2009) . At the risk of developing long-term complications from diabetes (Ogawa et al., 2002) , DM patients bear the tremendous burden physically, psychologically and economically. Screening asymptomatic diabetic patients will reduce the impact of diabetes complications (Harris et al., 2003) and offer more valuable prevention methods. Currently, the blood glucose test is the most popular clinical detection for diabetes but irregular blood glucose level, unfortunately, is not a good early indicator for diabetes diagnosis. Previous studies have shown that comprehensive analysis of various immune indicators, such as insulin, connecting peptide (C-peptide), glycosylated haemoglobin (HbA1C), C-reactive protein (CRP) and adiponectin, is more suited for early diagnostic of the asymptomatic prediabetes (Cavallo et al., 1992; John, 2003; Pajvani et al., 2004) . The standard test methods for these indicators, which include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and chemiluminescence immunoassay (CLIA), are usually based on microplates and automatic biochemistry analysers. Although these methods have high reliability, they require relatively large facilities and therefore are more or less restricted to the conditions of laboratory testing.
They are not suitable for off-site operation, which is crucial for providing fast, point-of-care type medical care for diabetes patients.
Recently, microfluidic systems as miniaturized diagnostic platforms have attracted considerable interest in recent years (Ohashi et al., 2009; Yager et al., 2006) . As a promising technique, microfluidics is replacing the conventional diagnostic systems for diabetes screening due to its advantages of low reagent consumption, short analysis time and multi-process integration (Dittrich et al., 2006; Henares et al., 2008; Huang et al., 2007) . In microfluidic systems, the traditional biochemical processes such as sample pretreatment, reagent transportation, mixing, reaction, separation, detection and product collection can be accomplished automatically on a single chip (Lin et al., 2010) . The portability characteristics of microfluidic systems, in particular, offer a great opportunity for widespread diabetes screening in remote areas. Polydimethysiloxane (PDMS) is a popular polymeric material employed in the fabrication of microfluidic devices owing to a number of advantages, including a simple fabrication process, biocompatibility, excellent optical transparency and permeability to gases (Wong and Ho, 2009) . The development of a PDMS-based microfluidic chip may provide a user-friendly, automatic platform for fast diagnosis of diabetes by measuring the concentration of serum insulin and other indicators.
Telemedicine is a fast and efficient tool for improving communication and co-operation between patients and doctors (Gomez et al., 2002; Wojcicki et al., 2001) . Officially, the term is defined as 'any transmission of medical information by means of telecommunication technology' (Azar and Gabbay, 2009 ). For diabetes, close monitoring of blood insulin, C-peptide and other indicators at home is a key element of disease management. However, without timely professional feedback, monitoring of these indicators has a somewhat lesser value (von Lode, 2005) . With the advancement of cyber technology, telemedicine is changing the healthcare models particularly in the way of healthcare delivery (Gomez et al., 1999) . The development of the Internet in particular offers a perfect agency for patients to acquire medical information from their physicians directly (Gomez et al., 2002) . For diabetes patients living in rural areas, this means obtaining professional diagnosis without leaving their homes, saving the time and cost of travelling. The combination of microfluidic devices and portable detectors capable of transmitting digital information through existing communication channels provides an integrated approach for point-of-care diabetes diagnosis and management (Martinez et al., 2008) . This paper describes a telemedicine system for diabetes patients that quantifies insulin in PDMS microfluidic devices and exchanges the test result with off-site specialists for medical evaluation. The integrated PDMS microfluidic system uses a double-antibody chemiluminescence immunoassay to measure serum insulin concentrations. The system consists of two pneumatic micropumps and one micromixer. The immunoreactions are conducted in the micromixer, utilizing immune microbeads to capture the target insulin. An optical detector is used for measuring the chemiluminescent light intensity, which is proportional to the concentration of the insulin measured. Compared with the coulometry of insulin determination (Mizutania et al., 2008) , an optical method is low cost and more sensitive. The performance of the microfluidic system is controlled both locally by wireless communication and remotely via the Internet, achieving the goal of local testing and processing while under the supervision of remote trained personnel. Medical doctors located off-site can then analyse the test results of the immune indicators and offer a professional opinion.
Materials and methods
The primary components of the telemedicine system include various PDMS-based microfluidic devices, a chemiluminescence detection unit and a wireless communication device such as a WiFi cellular phone, capable of quantifying the results of the microfluidic system and transmitting the digitized information off-site through the Internet. After receiving and analysing the test result, the off-site physician remotely adjusts the control parameters of the microfluidic system when necessary, and provides medical opinion along with other related information. Figure 1 demonstrates the architecture of the microfluidicbased telemedicine system. Plasma sample is injected into the microfluidic system, which carries out the necessary immune reactions automatically with remote assistance from off-site specialist. The local control system consists of a control circuit and a mini air pressure pump to adjust the performance of the microfluidic pump and micromixer. A photometer measures the chemiluminescent emission from the microfluidic system. As a communication tool, the WiFi phone conveys the control parameters and test result after accessing the mobile URL address. Through the Internet, these results are displayed in the individual interface on the diabetes specialist's computer.
System architecture
The rapid increase in mobile phone coverage and usage across the globe provides an excellent opportunity for telemedicine. The cellular communication industry is, and will continue to be, a global resource that can be leveraged for detecting disease. The telemedicine system is designed for unskilled personnel who can utilize the microfluidic chips to analyse plasma samples, and that shifts the processing and analysis responsibility from on-site to off-site personnel. The portable WiFi phone is used as a tool for controlling the biochemical process in the microfluidic devices as well as transmitting the test results. Ultimately, application-specific software will collect the digital data sent through the wireless communication infrastructure, and quantifies the results of the assays by comparison with standard curves. The role of the off-site physician would be to analyse the data and to recommend treatment.
Detection protocol
The magnetic bead-based chemiluminescent immunoassay for heterogeneous insulin detection is presented in Figure 2 . In this procedure, carboxyl-modified magnetic microspheres (Tianjin Baseline ChromTech Research Center, China) are mixed with EDAC (200 mg/ml) to conjunct primary insulin antibodies covalently (Figure 2a) . By injecting an appropriate amount of insulin antibody (Shanghai E. Star BioTechnology Co., China) into the solution, immune magnetic beads are produced (Figure 2b ). Taking advantage of the specific interaction between the immune beads and insulin (antigen; Shanghai E. Star BioTechnology Co.), the insulin molecules are recognized and the semi-sandwich structure is formed (Figure 2c ). After that, horseradish peroxidase (HRP)-labelled insulin antibodies (Shanghai E. Star BioTechnology Co.) are added to form the complete sandwich complexes (Figure 2d ). Through the use of an external magnet, the non-reactive insulin antibodies and antigens are washed away in each step. Without the interference materials, luminol and H 2 O 2 with the enhancer p-iodophenol are injected. Under the condition of alkalescence and catalysed by the HRP of the sandwich complexes, the luminol is rapidly oxidized by the H 2 O 2 and emits light at a wavelength of~425 nm with an intensity proportional to the amount of the HRP (Figure 2e ). Since the insulin and its secondary antibody are a one-to-one conjugation, the quantity of HRP connected to the secondary antibody is a direct measurement of the quantity of the insulin. The emitted light is quantified by the photometer.
The immune reaction processes are carried out semiautomatically in the microfluidic system. For the traditional biochemistry analysers, the mixture of immune magnetic beads and bio-samples should be incubated at 37°C for 60 min to recognize the target insulin. Following the incubation step, the non-reactive materials are washed manually and the insulin antibodies labelled with HRP are allowed to interact with the target insulin for 30 min. Finally, the unbound HRP-labelled insulin antibody is removed by washing. When HRP labeled insulin antibody compared with the conventional insulin detection process, the microfluidic system requires fewer reagents and shorter reaction time.
Results and discussion
The primary development tasks of the telemedicine system include microfluidic device design and fabrication, local detection system design including the hardware of local control circuit, automatic detection of insulin concentration, insulin calibration and the diabetes specialist interface. The need for portable and quantitative devices remains, however, for more effective systems, and especially for systems designed specifically for conditions in the developing world.
Microfluidic system
The microfluidic system consists of two PDMS pneumatic micropumps and one micromixer connected by Tygon tubings as shown in Figure 3 . Each micropump and micromixer consists of two thin PDMS layers sandwiched between two matching glass slides (Figure 3b ). In the micropump, the top PDMS layer contains a 100-mm-tall microchannel with one inlet and one outlet for fluid transport, while the bottom PDMS layer consists of three membrane-enclosed, serially connected air chambers. The three air chambers have different volumes. In the micromixer, the top PDMS layer consists of a fluid mixing chamber (2 mm diameter and 100 mm depth) with two y-shaped inlets and one outlet. Six air chambers with thin membranes and connected in series through serpentine microchannels reside in the bottom PDMS layer. Fabrication of the micropump and micromixer involves five major processing steps: SU-8 spin-coating, SU-8 patterning through photolithography, PDMS replication using SU-8 templates, PDMS demoulding from templates and PDMS-toglass bonding. The PDMS material was prepared by mixing the elastomer base and curing agent of Sylgard 184 (Sylgard 184A/B, Sil-More Industrial Ltd, USA) in a 10:1 ratio. Afterwards, it was spin-coated onto the SU-8 templates, degassed to remove air bubbles, and then thermal cured at 65°C for 2 h on a hot plate. The cured PDMS layers were removed from the templates and used as individual layers of the microfluidic devices. To provide mechanical support to the device, two glass slides were prepared. A diamond tip drill bit was used to drill holes in the glass slides to allow access to the PDMS layers. The top and bottom PDMS layers were bonded to the respective glass slides after an oxygen plasma treatment of the bonding surfaces. The PDMS-to-PDMS bonding was performed in a similar manner. The bonded device was then packaged with microfluidic connectors and Tygon tubings for introducing the sample and compressed air into the device.
The working principle of the pneumatic micropump and micromixer is similar. Both devices are regulated by compressed air pulses generated by electromagnetic valves (EMVs) and a compressed air source. The air pulses deflect the diaphragms of the air chambers in a sequential manner causing either fluid flow in the micropump or mixing in the micromixer. The flow rate of the micropump and the mixing efficiency of the micromixer are determined by the actuation pressure and frequency.
Local detection system
As an insulin detection device for unskilled personnel, the local detection system is designed to have the characteristics of automatic control, portability and wireless transfer of the digital test results. Figure 4 demonstrates the local integrated microfluidic system including the control part and the measurement part for insulin detection.
In addition to the two PDMS-based pneumatic micropumps and one micromixer, the detection system consists of a mini air compressor (Hargraves, D730A-23-01, Mooresville, NC, USA), which supplies compressed air to the pneumatic micropumps and micromixer, and a control circuit that produces square wave signals that open and close the EMVs (SMC Inc., S070M-5BG-32, Japan) to regulate the air flow (Zhan et al., 2010) . The air pressure and the EMV frequency are the most critical control parameters of the micropumps and micromixer. An air pressure sensor (Omega, DPG1000B-100G, Stamford, CT, USA) is utilized to monitor the air pressure. Chemiluminescence signals from the micromixer are detected by a photometer (RFL-1A, Remex Co., China). The micromixer is kept in a black box so that only light emission from the micromixing chamber is collected and detected by the photometer.
Control circuit
All the microfluidic devices in the telemedicine system are controlled by a custom-designed, programmable, integrated digital control system. Figure 5 shows the hardware design of the control circuit that regulates the EMV frequency. The Samsung S3C2440 embedded processor is a highly integrated chip with an ARM920T core. It is equipped with a 16/32-bit RISC microprocessor that is designed for hand-held devices, since it can be powered by batteries. Each output of the control circuit can generate independent multi-channel frequencies. Through the liquid crystal display (LCD), the output signals can be viewed together or individually. The power amplifier elevates the signals from the S3C2440 to the level that can drive the EMV. Utilizing WiFi wireless local area network communication, the amplitude and frequency of the EMV control signals can be adjusted through a cellular phone. This phone is also responsible for data collection from the insulin measurement and conveying this information to the operator. Figure 6 demonstrates a typical time-dependent chemiluminescent light intensity (RLU) signal captured from the micromixer during the immune reaction. The relationship is parabolic in nature and it takes about 1 min for the light intensity to reach its peak value. After reaching a peak value, the signal slowly decreases back to the base line level. In the present design, the peak chemiluminescence value is used to represent the concentration of HRP in the immune reaction, which is equivalent to the insulin concentration in the same reaction. To detect the insulin concentration automatically, the time-varying luminous intensity is digitized and the result is further processed to determine the peak value directly. Instead of the complete light-intensity curve, only information related to the peak value and therefore the corresponding insulin concentration is recorded. This method minimizes the detection time and prevents unnecessary information from being transferred over the communication resources.
Chemiluminescence reaction

Insulin sensitivity and calibration
The immunoreactions are conducted in the integrated microfluidic system as shown in Figure 3 . Following each immune reaction, washing procedures are carried out with the help of a permanent magnet, which is fixed to the outer surface of the mixing chamber. The micromixer used for the chemiluminescence measurement of the insulin antigen between the immune microbeads and HRP-labelled antibodies is placed in the dark box of the photometer to reduce noise and improve sensitivity. The mixer is operated at the optimal working conditions. The solution that contains the HRP-labelled insulin sandwich complex, the hydrogen peroxide (7.5310 23 M), and the enhancer p-iodophenol (3 mg/ml) is injected into the mixing chamber via one inlet of the micromixer, while another inlet is used to inject the luminol solution (7.8310 23 M). The two solutions are fed into the mixing chamber simultaneously, and allowed to achieve a complete reaction (Figure 2e ). The concentrations of the chemicals used for this chemiluminescencent measurement were optimized in advance. Figure 7 is a typical sensitivity curve of the insulin immunoassay, demonstrating the relationship between the chemiluminescence signal and the corresponding insulin concentration. As indicated by the figure, the insulin detection limit of the microfluidic system is about 4310 210 M, which generally meets the present clinical requirement for diabetes care and screening. The insulin concentration forms a relatively linear relationship with the chemiluminescent light intensity. The total reaction time of the immunoassay in the microfluidic system is about 10 min. This is significantly faster than the conventional laboratory-based method, which requires about 120 min.
In addition to insulin, other immune indicators for diabetes such as C-peptide, HbA1C, CRP and adiponectin can be detected in a similar manner in the microfluidic system by using different sets of reagents. It is envisioned that a parallel microfluidic system consisting of highly integrated micropumps and micromixers can be developed for processing multiple indicators simultaneously using the same plasma sample. The combined result will provide physicians with comprehensive information necessary for accurate diagnosis and treatment of diabetes.
Diabetes specialist interface
The screen display interface for the off-site diabetes specialist is shown as Figure 8 . The control section is a display of the actuation frequency and air pressure control panel. When the control parameters of the microfluidic system require adjustment, the driving frequency of the EMV and the pressure can be regulated through this section. The levels of the diabetes indicators tested are shown in the result section. Based on the information displayed, the off-site specialist can either comment on the test results or issue other medical instructions. If the video communication option is checked, another window would be opened to produce a live video stream from the camera, which shows both the assay site and the off-site physician.
Conclusions and future perspectives
The current study demonstrated a cyber-based telemedicine system for insulin detection using an integrated PDMS microfluidic system. By combining microfluidic technology with supporting electronics and communication hardware, this technology provides a useful tool to advance primary healthcare for diabetes patients in rural areas where dependable testing facilities are lacking. Through the Internet, the telemedicine system offers real-time communication between the patients (or medical staff) and diabetes specialists who can provide detailed analysis based on the test results obtained remotely. The insulin detection limit of the microfluidic system is 4310 210 mol/l, which meets the common requirement for current clinical studies on diabetes. The reaction time of the immunoreactions in the microfluidic system is about 10 min. When compared with the conventional method, which tends to be large in size and slow in detection time, the microfluidic-based telemedicine system is ideally suited for conducting large-scale diabetes screening of the general population.
The present paper describes the experimental result of only one diabetes indicator: insulin. Further studies will be required expand the detection technique into multiple indicators needed for a comprehensive diagnosis of diabetes. In addition, it is envisioned that future development of the telemedicine system will involve close collaboration with diabetes specialists who will be the ultimate users of the developed system. Their advice will not only improve the dependability of the system but also the ease-of-use factor, which will be important for promoting usage of the system.
